图文展示3264

图文展示3264

副标题

Semaglutide
Liraglutide
Epinephrine
Norepinephrine Bitartrate
Ganirelix Acetate
Semaglutide

CAS:910463-68-2

Molecular Formula CHNO

Purity>99% (for injection),>98% (for tablets)

Application: Used for the treatment of type II diabetes.

Market potential: By 2022, the global sales of Semaglutide preparations will be approximately USD 24.3 billion, in a high-growth phase, with huge development potential.
                                                                                                                           
                                                                                                    In case any product is still in valid patent, it will not be used for any commercial purpose.
Liraglutide

CAS:204656-20-2

Molecular Formula CHNO

Purity>95%, >99% (two specifications)

Application: Used for the treatment of type II diabetes and obesity.
Market Potential: In 2022, the global sales of various specifications of Liraglutide injection were approximately USD 6.7 billion, with huge market capacity and broad prospects.

Epinephrine


CAS:51-43-4


Molecular Formula:CH₁₃NO

Purity>99%

Application: Used for severe respiratory distress caused by bronchospasm, cardiac arrest caused by various reasons, and can be used for cardiopulmonary resuscitation. It can also be used to relieve drug-induced anaphylactic shock.


Market Potential: In 2022, the global sales of Epinephrine were approximately USD 2.4 billion, with huge market capacity and broad prospects.
Norepinephrine Bitartrate

CAS:108341-18-0

Molecular Formula:C₈H₁₁NO₃· C₄H₆O₆· H ₂O

Purity>99%

Application: Used to treat diseases with sudden drop in bloodpressure, such as cardiogenic shock, anesthesia overdose, hemorrhagic shock,
heart failure, toxic shock, and other critical illnesses.
Market Potential: In 2022, the global sales of Norepinephrine Bitartrate were approximately USD 500 million.
 
Ganirelix Acetate

CAS:123246-29-7


Molecular Formula:CHNOCl·CHCOOH

Purity>99%

Application: This product is used in women undergoing controlled ovarian stimulation (COS) in assisted reproductive technology (ART) to prevent early onset of luteinizing hormone (LH) peaks.


Market Potential: In 2022, the global sales of Ganirelix Acetate were approximately USD 230 million.